中晚期卵巢癌术后顺铂腹腔联合紫杉醇静脉化疗的临床观察

目的:观察顺铂腹腔联合紫杉醇静脉化疗治疗中晚期卵巢癌术后患者的临床疗效和安全性.方法:回顾性分析我院2006-01-2009-12行细胞减灭术Ⅱ～Ⅳ期卵巢癌76例患者,顺铂腹腔联合紫杉醇静脉化疗36例为治疗组,并以同期行顺铂联合紫杉醇静脉化疗患者40例作为对照.比较两组患者无进展生存期(PFS)、生存率和不良反应.结果:治疗组PFS 27个月,对照组PFS 23个月,P＜0.05.治疗组1、2和3年生存率分别为97.22％(35/36)、94.44％(34/36)和88.88％(32/36),对照组1、2和3年生存率分别为95.00％(38/40)、90.00％(36/40)和77.50％(31/40).治化疗组呕吐及肾功能损伤低于对照组,而腹痛高于对照组.结论:顺铂腹腔联合紫杉醇静脉化疗治疗中晚期卵巢癌术后患者可延长患者PFS及生存率,毒副反应轻,值得临床应用.

Clinical effect of postoperative intraperitoneal chemotherapy with cisplatin combined with intravenous paclitaxel chemotherapy for the moderately or advanced ovarian cancer

OBJECTIVE: To observe the clinical efficacy and safety of postoperative intraperitoneal chemotherapy with cisplatin combined with intravenous paclitaxel chemotherapy for the moderately or advanced ovarian cancer.METHODS: From Jan.2006 to Dec.2009,76 patients with ovarian cancer in Ⅱ-Ⅳstage after cytoreductive surgery were analyzed retrospectively.And 36 ovarian cancer patients were treated with intraperitoneal cisplatin chemotherapy and intravenous paclitaxel chemotherapy(treatment group).Totally 40 ovarian cancer patients accepted intravenous chemotherapy with cisplatin and paclitaxel(control group).The progression free survival(PFS),survival rate and adverse reaction of two groups were observed.RESULTS: The PFS in treatment group was 27 months,The PFS in control group was 23 months,the differences was significant(P<0.05).One,two and three year survival rates in treatment and control group were 97.22%(35/36),94.44%(34/36) and 88.88%(32/36) respectively,that in IV group were 95.00%(38/40),90.00%(36/40) and 77.50%(31/40) respectively.Vomiting and renal function failure was obviously lower and stomachache was obviously higher in intraperitoneal and intravenous chemotherapy group than the control group.CONCLUSION: The postoperative intraperitoneal cisplatin chemotherapy combined with intravenous paclitaxel chemotherapy has obviously prolonged PFS and survival rate,light toxicity and of patients with the moderately or advanced ovarian cancer,and is well worth clinical popularizing and application.